Determining the Effect of Vitamin D, Dyslipidemia and Microvascular in Patients With Type 2 Diabetes
NCT ID: NCT04439474
Last Updated: 2020-06-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
187 participants
INTERVENTIONAL
2018-10-10
2020-02-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Vitamin D Supplementation in Type 2 Diabetes
NCT01854463
Vitamin D Supplementation on Cardiovascular Risk Factors
NCT01412710
A Trial to Study the Effect of Vitamin D Supplementation on Glucose and Insulin Metabolism in Centrally Obese Men
NCT00347542
Efect Supplementation Vitamin D in Diabetes Mellitus Type 2
NCT07019415
Effect of Vitamin D Supplementation on Hemoglobin A1c
NCT01354262
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with vitamin D deficiency
This group receives 50,000 units of vitamin D3 daily for up to 8 days until the serum level of vitamin D reaches above 30 ng/ml.
Vitamin D3
For up to 8 days, 50,000 units of vitamin D3 are given daily to patients in the first group so that the serum level of vitamin D reaches above 30 g / ml.
Patients without vitamin D deficiency
Participants in this group receive only their usual treatments
Routine treatment
In this group, patients receive their usual medications and treatments
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vitamin D3
For up to 8 days, 50,000 units of vitamin D3 are given daily to patients in the first group so that the serum level of vitamin D reaches above 30 g / ml.
Routine treatment
In this group, patients receive their usual medications and treatments
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Having conscious satisfaction
Exclusion Criteria
* Patients with a history of renal failure
* Patients with a history of vitamin D intake and calcium-containing compounds
* Patients with a history of liver disease
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Baqiyatallah Medical Sciences University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohammad Sadegh Bagheri Baghdasht
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mohammad Sadegh Bagheri Baghdasht
Tehran, , Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IR.BMSU.REC.1392.32
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.